dslogo
azlogo

DESTINY-Breast03: Asia Subgroup Efficacy Results (May 21, 2021 DCO Date)

Progression-Free Survival

Progression-Free Survival11. Im S-A, Xu B, Kim, S-B, et al. Trastuzumab deruxtecan vs T-DM1 in HER2+ mBC in Asian subgroup: Results of the randomized phase 3 study DESTINY-Breast03 [presentation]. Presented at: the Japanese Society of Medical Oncology Annual Meeting 2022; February 17-19, 2022. Presentation PS2-1.

PFS by BICR.11. Im S-A, Xu B, Kim, S-B, et al. Trastuzumab deruxtecan vs T-DM1 in HER2+ mBC in Asian subgroup: Results of the randomized phase 3 study DESTINY-Breast03 [presentation]. Presented at: the Japanese Society of Medical Oncology Annual Meeting 2022; February 17-19, 2022. Presentation PS2-1.

PFS by BICR.11. Im S-A, Xu B, Kim, S-B, et al. Trastuzumab deruxtecan vs T-DM1 in HER2+ mBC in Asian subgroup: Results of the randomized phase 3 study DESTINY-Breast03 [presentation]. Presented at: the Japanese Society of Medical Oncology Annual Meeting 2022; February 17-19, 2022. Presentation PS2-1.

<p>PFS by BICR.<span class="tooltip"><span class="tooltip-text"><sup>1</sup></span><span class="tooltip-content" style="display: none;"><span>1. Im S-A, Xu B, Kim, S-B, et al. Trastuzumab deruxtecan vs T-DM1 in HER2+ mBC in Asian subgroup: Results of the randomized phase 3 study DESTINY-Breast03 [presentation]. Presented at: the Japanese Society of Medical Oncology Annual Meeting 2022; February 17-19, 2022. Presentation PS2-1.</span></span></span></p>

Note: Median PFS follow-up for T-DXd was 16.5 months and for T-DM1 was 15.8 months

PFS by Investigator Assessment.11. Im S-A, Xu B, Kim, S-B, et al. Trastuzumab deruxtecan vs T-DM1 in HER2+ mBC in Asian subgroup: Results of the randomized phase 3 study DESTINY-Breast03 [presentation]. Presented at: the Japanese Society of Medical Oncology Annual Meeting 2022; February 17-19, 2022. Presentation PS2-1.

PFS by Investigator Assessment.11. Im S-A, Xu B, Kim, S-B, et al. Trastuzumab deruxtecan vs T-DM1 in HER2+ mBC in Asian subgroup: Results of the randomized phase 3 study DESTINY-Breast03 [presentation]. Presented at: the Japanese Society of Medical Oncology Annual Meeting 2022; February 17-19, 2022. Presentation PS2-1.

<p>PFS by Investigator Assessment.<span class="tooltip"><span class="tooltip-text"><sup>1</sup></span><span class="tooltip-content" style="display: none;"><span>1. Im S-A, Xu B, Kim, S-B, et al. Trastuzumab deruxtecan vs T-DM1 in HER2+ mBC in Asian subgroup: Results of the randomized phase 3 study DESTINY-Breast03 [presentation]. Presented at: the Japanese Society of Medical Oncology Annual Meeting 2022; February 17-19, 2022. Presentation PS2-1.</span></span></span></p>

Overall Survival

Overall Survival11. Im S-A, Xu B, Kim, S-B, et al. Trastuzumab deruxtecan vs T-DM1 in HER2+ mBC in Asian subgroup: Results of the randomized phase 3 study DESTINY-Breast03 [presentation]. Presented at: the Japanese Society of Medical Oncology Annual Meeting 2022; February 17-19, 2022. Presentation PS2-1.

OS.11. Im S-A, Xu B, Kim, S-B, et al. Trastuzumab deruxtecan vs T-DM1 in HER2+ mBC in Asian subgroup: Results of the randomized phase 3 study DESTINY-Breast03 [presentation]. Presented at: the Japanese Society of Medical Oncology Annual Meeting 2022; February 17-19, 2022. Presentation PS2-1.

OS.11. Im S-A, Xu B, Kim, S-B, et al. Trastuzumab deruxtecan vs T-DM1 in HER2+ mBC in Asian subgroup: Results of the randomized phase 3 study DESTINY-Breast03 [presentation]. Presented at: the Japanese Society of Medical Oncology Annual Meeting 2022; February 17-19, 2022. Presentation PS2-1.

<p>OS.<span class="tooltip"><span class="tooltip-text"><sup>1</sup></span><span class="tooltip-content" style="display: none;"><span>1. Im S-A, Xu B, Kim, S-B, et al. Trastuzumab deruxtecan vs T-DM1 in HER2+ mBC in Asian subgroup: Results of the randomized phase 3 study DESTINY-Breast03 [presentation]. Presented at: the Japanese Society of Medical Oncology Annual Meeting 2022; February 17-19, 2022. Presentation PS2-1.</span></span></span></p>

Abbreviations

ADC = antibody-drug conjugate

;

BICR = blinded independent central review

;

DCO = data cut-off

;

ECOG = Eastern Cooperative Oncology Group

;

HR = hazard ratio

;

IHC = immunohistochemistry

;

ISH = in situ hybridization

;

NE = not evaluable

;

mo = month

;

mOS = median overall survival

;

mPFS = median progression-free survival

;

OS = overall survival 

;

PFS = progression-free survival 

;

PS = performance status

;

T-DXd = trastuzumab deruxtecan

;

T-DM1 = trastuzumab emtansine

;

TKI = tyrosine kinase inhibitor

References

1. Im S-A, Xu B, Kim, S-B, et al. Trastuzumab deruxtecan vs T-DM1 in HER2+ mBC in Asian subgroup: Results of the randomized phase 3 study DESTINY-Breast03 [presentation]. Presented at: the Japanese Society of Medical Oncology Annual Meeting 2022; February 17-19, 2022. Presentation PS2-1.

Please note that this content may contain some data and/or patient populations which are considered off-label in your country. Providing this information does not constitute any recommendation for use. AstraZeneca is providing this material as an information service and professional courtesy. 

To help us improve our content for health care professionals, please take this short survey.

Feedback Survey

©2023 AstraZeneca. All rights reserved.